【Abstract】 Objective To investigate the influence of memantine combined with donepezil on MoCA, ADL and serum CRP, PARK7 in patients with Parkinson's disease. Methods 90 Parkinson's disease in our hospital were selected and divided into the observation group (49 cases) and the control group (40 cases), according to treatment methods. The control group was given donepezil treatment, and the observation group was given memantine combined with donepezil treatment. Clinical data of the two groups were retrospectively analyzed, the clinical effect, cognitive function, ADL of the two groups were compared and analyzed. The adverse reactions during the treatment were recorded. Results Total effective rate of the observation group (7750%) was significantly higher than that of the control group (9592%) (P＜005). At 12 weeks after treatment, UPDRS total score, MMSE, MoCA and ADL scores of the two groups were significantly improved. The UPDRS total score of the observation group was lower than that of the control group. MMSE, MoCA, ADL scores were higher than those of the control group. The difference was statistically significant （P＜005）. At 12 weeks after treatment, serum CRP, PARK7, NT3 levels were significantly improved. Serum CRP, PARK7 levels in the observation group were lower than those in the control group. The serum NT3 level was higher than that in the control group （P＜005）. The adverse reaction rate of the control group （1250%）was higher than that in the observation group（1224%）（P＞005）. Conclusion Memantine combined with donepezil in patients with Parkinson's disease have better clinical effect, which can effectively improve the illocutionary function and cognitive function, reduce the serum CRP, PARK7 levels and increase the serum NT3 level.